MaxCyte Inc (MXCT) Receives “Buy” Rating from Panmure Gordon

Panmure Gordon reiterated their buy rating on shares of MaxCyte Inc (LON:MXCT) in a research report report published on Tuesday. They currently have a GBX 338 ($4.56) price objective on the stock.

Shares of MaxCyte (LON MXCT) opened at 247.50 on Tuesday. The company’s market cap is GBX 107.76 million. The company has a 50-day moving average of GBX 245.88 and a 200-day moving average of GBX 258.22. MaxCyte has a 1-year low of GBX 83.00 and a 1-year high of GBX 305.00.

TRADEMARK VIOLATION WARNING: “MaxCyte Inc (MXCT) Receives “Buy” Rating from Panmure Gordon” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/09/20/maxcyte-inc-mxct-receives-buy-rating-from-panmure-gordon.html.

MaxCyte Company Profile

MaxCyte, Inc focuses on cell-based medicines. The Company’s cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company’s products include instruments, processing assemblies and insourcing services.

Receive News & Ratings for MaxCyte Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply